Related Experiment Videos
CD98hc (SLC3A2) interaction with beta 1 integrins is required for transformation
Neil C Henderson1, Elizabeth A Collis, Alison C Mackinnon
1Lung Inflammation Group, Medical Research Council Centre for Inflammation Research, University of Edinburgh Medical School, Edinburgh EH8 9XD, Scotland, UK.
The Journal of Biological Chemistry
|October 16, 2004
Summary
CD98hc (SLC3A2) protein promotes tumor growth by interacting with beta(1) integrins. This interaction activates signaling pathways crucial for cancer cell transformation and survival, offering a potential therapeutic target.
Area of Science:
- Cell Biology
- Molecular Oncology
- Biochemistry
Background:
- CD98hc (SLC3A2) is highly expressed on human tumor cells.
- CD98hc associates with beta(1) integrins.
Purpose of the Study:
- Investigate the role of CD98hc in tumor cell growth.
- Elucidate the mechanism of CD98hc-mediated oncogenesis.
Main Methods:
- Utilized chimera proteins of CD98hc and CD69.
- Assessed anchorage- and serum-independent growth.
- Analyzed phosphoinositol 3-hydroxykinase and focal adhesion kinase activation.
Main Results:
- CD98hc expression promotes anchorage- and serum-independent growth.
- CD98hc/beta(1) integrin association is critical for oncogenic activity.
- The transmembrane domain of CD98hc is essential for integrin association.
- Specific amino acids (82-87) in CD98hc are vital for its oncogenic potential.
Conclusions:
- CD98hc facilitates tumor promotion through beta(1) integrin signaling.
- The CD98hc/beta(1) integrin complex is a novel mechanism in cancer transformation.
- Targeting the CD98hc/beta(1) integrin interaction may offer new cancer therapies.